Diabetes Dibi Temedica launched Dibi, a digital companion app for Type 2 diabetes patients sponsored by Novo Nordisk Pharma GmbH, signaling a strong partnership runway with major pharma sponsors and digitized patient engagement opportunities.

Strategic Advisory High value advisory capability evidenced by hiring former Gematik CEO Markus Leyck Dieken as expert advisor, suggesting credibility with regulatory, digital health standards, and payer-facing integrations that can be leveraged in sales to pharma and healthcare customers.

Data Platform Earlier rollout of the Permea data platform indicates Temedica’s focus on real world data and analytics infrastructure, presenting opportunities to offer data integration, insights, and analytics services to pharma clients seeking evidence generation and targeted go-to-market insights.

Partnership Momentum Strategic collaborations with Bristol Myers Squibb on psoriasis digital companion projects and ongoing pharma sponsorships point to a track record of co-development and co-branding opportunities that can be extended to new disease areas or patient cohorts.

Funding & Growth Recent funding activity including a €25M Series B extension and overall funding of around €26M underscores growth trajectory and capacity to scale services, enabling sales pitches around expanded SKUs, platform rollouts, and larger pilot programs.